ArticleDiscover oncology2025
Global trends in prostate cancer burden among adults aged 80 years and older from 1990 to 2021 based on the global burden of disease 2021.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aimed to investigate the global, regional, and national burden of prostate cancer (PCa) among adults aged 80 years and older (≥ 80 years) from 1990 to 2021.
methodsUsing data from the Global Burden of Disease 2021 (GBD 2021) study, we systematically analyzed PCa incidence, mortality, and disability-adjusted life years (DALYs) among populations aged ≥ 80 years across 204 countries and territories. Patients were grouped by age (80-84, 85-89, 90-94, and ≥ 95 years), and burden was assessed by geographic region and socio-demographic index (SDI). Temporal trends were examined using Joinpoint regression to calculate the annual percentage change (APC) and average annual percentage change (AAPC), with 95% confidence intervals. Regional disparities were visualized using map-based analysis, and the contributions of risk factors were assessed. Bayesian age-period-cohort (BAPC) models projected future trends to 2040.
resultsFrom 1990 to 2021, the incidence rate of PCa in those aged ≥ 80 years showed an overall decline (AAPC = -0.43%, 95% CI -0.52 to -0.35), while the absolute number of incidence, deaths, and DALYs increased steadily across all age groups, potentially associated with population aging. Incidence and mortality rates peaked in the mid-1990s, then fell most rapidly between 2007 and 2013, especially in high- and high-middle SDI regions. In contrast, low- and low-middle SDI regions experienced slower declines or persistent increases. In 2021, the highest incidence and mortality rates occurred in select Caribbean nations, while the lowest rates were found in Central Asia. Smoking remained the leading modifiable risk factor, but its impact decreased in higher SDI regions. Dietary factors, especially milk and calcium intake, were protective. BAPC modeling suggests that the decline in incidence, mortality, and DALYs is likely to continue through 2040, although uncertainty in projections increases over time, especially in low-SDI regions.
conclusionsWhile substantial global progress has been made in reducing PCa incidence, mortality, and DALYs among adults aged ≥ 80 years, significant disparities persist, especially in low-resource settings, mainly due to differences in detection, treatment, and risk reduction strategies. Ongoing efforts to promote equitable access to early detection, effective treatment, and risk factor mitigation are essential to further reduce the burden of PCa in the aging population worldwide.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.